Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 11 September 2012 | By Alexander Gaffney, RAC
Australia's Therapeutic Goods Administration (TGA) is beginning the process of revising its code of good manufacturing practices (GMPs) for the manufacture of blood and tissue products, the agency announced on 11 September.
The revisions will eventually update TGA's August 2000 code, GMPs for Blood and Tissues, and will involve a 12-month implementation period once finalized.
TGA said it anticipates making two primary revisions to the code: a revised portion dealing specifically with human blood, blood components, human tissues and human cellular therapy products and another portion establishing new standards for donor selection, testing and disease minimization.
Until the new code is released, sponsors should continue to comply with the existing regulations found in the August 2000 version of GMPs for Blood and Tissues and Appendix 4 of the Australian Regulatory Guidelines for Biologicals, explained TGA.
TGA - Revising the Code of GMP for blood and tissues
Tags: Tissue, Donor, HCT/Ps, Blood Products, Latest News, australia, GMPs